Jeffrey Jackson, MD
Dermatopathology · Elkins, WVNPI 1780611590
Payments from drug & device makers
Across 290 payments — averaging $462.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$131K
- Journey Medical Corporation$1K
- Johnson & Johnson$219
- Novartis$198
- Lilly USA, LLC$180
- Sun Pharmaceutical Industries Inc.$144
- plus $940 from 21 others
What the payments were for
- Speaking & faculty fees$121,25090%
- Travel & lodging$5,1974%
- Food & beverage$7,6316%
- Education$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 188 | $131,032 |
| Journey Medical Corporation | 18 | $1,468 |
| Johnson & Johnson | 14 | $219 |
| Novartis | 10 | $198 |
| Lilly USA, LLC | 9 | $180 |
| Sun Pharmaceutical Industries Inc. | 6 | $144 |
| Prugen, Inc. Pharmaceuticals | 2 | $103 |
| UCB, Inc. | 5 | $84 |
| Regeneron Healthcare Solutions, Inc. | 4 | $81 |
| Mayne Pharma Commercial LLC | 4 | $79 |
| Incyte Corporation | 3 | $69 |
| Pfizer | 4 | $61 |
| E.r. Squibb & Sons, L.L.C. | 3 | $54 |
| Organogenesis Inc. | 1 | $50 |
| Bristol Myers Squibb | 2 | $43 |
| Mission Pharmacal Company | 3 | $42 |
| Arcutis Biotherapeutics, Inc. | 2 | $38 |
| LEO Pharma Inc. | 2 | $35 |
| Galderma Laboratories, L.p. | 2 | $32 |
| Amgen | 1 | $29 |
| Medline Industries LP | 1 | $29 |
| Sanofi | 1 | $23 |
| Boehringer Ingelheim | 1 | $21 |
| DUSA Pharmaceuticals, Inc. | 1 | $20 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $16 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $16 |
| GSK | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few dermatopathology providers in West Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 19 | $400,586 |
| Humira(Cf) PenAdalimumab | 11 | $74,487 |
| Clobetasol Propionate | 136 | $4,415 |
| Dapsone | 40 | $3,589 |
| Doxycycline Hyclate | 82 | $3,163 |
| Ketoconazole | 131 | $2,804 |
| Metronidazole | 54 | $2,618 |
| Triamcinolone Acetonide | 146 | $2,156 |
| Desonide | 31 | $1,871 |
| Mupirocin | 89 | $743 |
| Betamethasone Dipropionate | 11 | $652 |
| Clindamycin Phosphate | 20 | $625 |
| Hydroxychloroquine Sulfate | 11 | $498 |
| ValacyclovirValacyclovir Hcl | 20 | $357 |
| Terbinafine Hcl | 19 | $210 |
Paid to pharmacies, not to this prescriber.
Other dermatopathology in Elkins
- Adeel AhmadBeckley$1K
- Colleen BeattyMorgantown$280
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.